Breast Cancer

Anna Weiss, MD, discusses the significance of various imaging modalities in patients with breast cancer.

Kari Wisinski, MD, highlights treatments for HER2– breast cancer, the role of chemotherapy in TNBC, and the benefits of T-DXd for brain metastases.

The Nectin-4/CD137 Bicycle–targeted immune cell agonist BT7480 had antitumor activity in patients with Nectin-4– and CD137-expressing tumors.

Kari Wisinski, MD, discusses factors that influence her decision between CDK4/6 inhibitors for patients with treatment-naive, HR+ metastatic breast cancer.

Sheldon M. Feldman, MD, discusses the significance of the new classification of HER2-low breast cancer and how this affects HER2+ breast cancer treatment

Dana Zakalik, MD, discusses the critical role of genetic testing in managing breast cancer.

Alberto Montero, MD, MBA, CPHQ, discusses the mechanism of action and potential advantages of the mutant-selective PI3Kα inhibitor STX-478 in solid tumors.

(Z)-endoxifen significantly reduced mammographic breast density and was generally well tolerated in premenopausal women screened for breast cancer.

Jairam Krishnamurthy, MD, FACP, discusses the use of mutation status to inform treatment sequencing in HR-positive, HER2-negative metastatic breast cancer.

Here is your snapshot of all therapeutic options that the FDA approved in October 2024 spanning tumor types.

Lasofoxifene was well tolerated and had early activity signals in patients with HR-positive, HER2-negative, locally advanced breast cancer.

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.

This roundup includes exclusive insights from 23 clinicians and key data on the top abstracts coming out of the 2024 ESMO Annual Meeting.

Deena Mary Atieh Graham, MD, discusses a pilot study evaluating RAGE inhibition to reduce therapy-related cardiotoxicity in early-stage breast cancer.

Hope Rugo, MD, FASCO, discusses the FDA approval of inavolisib, how it will be incorporated into care, and the patient population evaluated in INAVO120.

Sheldon M. Feldman, MD, discusses disparities, post-treatment care, and technological advancements in breast cancer during Breast Cancer Awareness Month.

Docetaxel treatment was associated with significantly less taxane-induced peripheral neuropathy vs paclitaxel in Black patients with breast cancer.

The FDA has announced that BioZorb Markers and BioZorb LP Markers should no longer be used.

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the inner workings of oncology: https://rb.gy/bvumdn.

Sheldon M. Feldman, MD, discusses the importance of personalized medicine in breast cancer during Breast Cancer Awareness Month.

The October 2024 NCCN Clinical Practice Guidelines in Oncology for breast cancer recommend ribociclib plus an AI in adjuvant HR+/HER2– early breast cancer.

Sheldon M. Feldman, MD, discusses how the use of personalized medicine has evolved in breast cancer management.

Sheldon M. Feldman, MD, discusses the importance of Breast Cancer Awareness Month as well as timely screening and early detection.

Jairam Krishnamurthy, MD, FACP, discusses the selective use of CDK4/6 inhibitors after prior progression on these agents in patients with breast cancer.

Xiaojia Wang, MD, discusses findings for ivonescimab plus chemotherapy in metastatic triple-negative breast cancer.